Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joshua Tulk has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recording and reporting of adverse events during a randomized controlled trial of cognitive behavioural therapy for insomnia (CBT-I) among cancer survivors

    by Krista M. Greeley, Rachel M. Lee, Joshua Tulk, Scott V. Harding, Yanqing Yi, Kris Aubrey-Bassler, Sheila N. Garland

    Sleep disturbances are one of the biggest barriers to resuming normal functioning following cancer treatment. Cognitive behavioral therapy for insomnia (CBT-I) has demonstrated efficacy in cancer survivors but few studies have recorded adverse events (AEs) that occur during treatment. The purpose of this study was to report the prevalence, severity, and attribution of AEs during CBT-I with cancer survivors. Cancer survivors from Atlantic Canada with insomnia and comorbid cognitive impairment were recruited to participate in a randomized controlled trial of CBT-I. Participants reported the prevalence, severity, and attribution of AEs at mid-treatment (4 weeks) and post-treatment (8 weeks). The likeliness of AEs being related to treatment was also rated by an independent clinician. Of the 122 cancer survivors who completed treatment (Mage = 60.3, 77.9% women), 72 reported a total of 197 AEs. At mid-treatment, participants reported 113 AEs, but only 11 were rated as being attributed to the intervention. At post-treatment, participants did not report any AEs attributed to the intervention. An independent rater attributed more AEs to the treatment than the participants at both time points (4 weeks: 16 vs. 11, 8 weeks: 1 vs. 0). Gender (p = .014) and pre-treatment anxiety (p < .001) were associated with reporting an AE. CBT-I is a safe treatment that is well-tolerated by cancer survivors. The majority of participants did not experience AEs that could be attributed to the treatment. Clinicians should continue to recommend CBT-I as the first-line treatment for cancer survivors experiencing insomnia symptoms. This study is a secondary analysis of a randomized controlled trial titled ‘Addressing Cancer Treatment-Related Insomnia Online in Atlantic Canada (ACTION) study’ ( https://www.clinicaltrials.gov/search?cond=NCT04026048 identifier: NCT04026048).


  • Factors associated with significant improvement in cancer-related fatigue after completing cognitive behavioral therapy for insomnia in cancer survivors

    by Krista M. Greeley, Joshua Rash, Joshua Tulk, Josée Savard, Melanie Seal, Robin Urquhart, John Thoms, Kara Laing, Emily Fawcett, Sheila N. Garland

    Purpose Cancer-related fatigue (CRF) can be a persistent and severe consequence of cancer treatment. Cognitive behavioral therapy for insomnia (CBT-I) can improve CRF in those with insomnia comorbid with cancer. This secondary analysis of a randomized controlled trial investigated what proportion of participants benefit and the factors associated with an improvement in CRF following CBT-I. Methods Atlantic Canadian cancer survivors (N = 121) with insomnia disorder and perceived cognitive impairment symptoms were recruited to participate in a randomized controlled trial of CBT-I. Fatigue was measured using the Multidimensional Fatigue Symptom Inventory–Short Form. Univariable and multivariable binary logistic regressions were used to assess clinical, symptom, and demographic factors associated with a significant improvement in CRF after CBT-I. Results The majority (75%) of the sample (Mage = 60.12 years, 77% women, 45% breast cancer) experienced a significant reduction in CRF symptoms following the intervention. Being younger (under 55), being female, having anxiety, and undergoing chemotherapy were associated with a greater likelihood of improvement in CRF at the univariable level. At the multivariable level, only younger age was significantly associated with an improvement in CRF after CBT-I. Conclusion CBT-I can effectively reduce CRF in cancer survivors who also experience insomnia. Differences in sleep patterns and/or the number of comorbid physical health concerns between younger and older people may explain why CBT-I improved CRF more in younger participants. Future research is needed to better understand the demographic, symptom, and clinical variables that may influence treatment response. Trial registration This is a secondary analysis of a registered randomized controlled trial (clinicaltrials.gov identifier: NCT04026048).


  • The effect of insomnia treatment on work productivity and related costs among cancer survivors with insomnia and comorbid perceived cognitive impairments: A secondary analysis of a randomized controlled trial

    by Joshua Tulk, Lynn Gambin, Sondria Browne, Kara Laing, Joshua A. Rash, Josée Savard, Melanie Seal, John Thoms, Robin Urquhart, Sheila N. Garland

    Purpose This secondary analysis of a randomized clinical trial aimed to understand the cost-effectiveness of cognitive behavioral therapy for insomnia (CBT-I) in improving absenteeism (i.e., time away from work) and presenteeism (i.e., unproductivity while at work) among cancer survivors. Methods A total of 55 currently employed mixed cancer survivors who met DSM-5 criteria for insomnia disorder and self-reported cognitive impairments were randomized to receive seven weekly, individual CBT-I sessions immediately or after a waiting period. Participants completed the Work Productivity and Activity Impairment Questionnaire (WPAI). Information from participants and the Labour Force Survey (LFS) were used to calculate costs. Education-adjusted mixed-effects models using intention-to-treat principles assessed immediate and longer-term effects of treatment on work productivity. Results While CBT-I was not associated with significant improvements in absenteeism, the treatment group reported a 23.5-point reduction in presenteeism post-treatment, compared to a 0.45-point decrease in the waitlist control group. Improvements in presenteeism were maintained at 6-month follow-up. The mean cost of total work productivity loss was CAD627.59 per person per week before beginning CBT-I. Treatment resulted in a 48.4%, 44.6%, and 30.5% reduction in lost productivity immediately, 3 and 6 months post-treatment, respectively. Total cost savings for the first year after treatment, adjusting for treatment costs, were estimated at CAD 9478.82. Conclusions Intervening upon late and long-term effects of cancer treatment (e.g., sleep, fatigue, cognitive impairment) through CBT-I produces meaningful and durable improvements in work productivity, particularly presenteeism. Implications for Cancer Survivors With appropriate treatment, survivors can address side effects and increase productivity, but additional work is needed to improve access to and coverage for evidence-based interventions.


  • Open Access

    Impact and Mechanisms of Cognitive Behavioural Therapy for Insomnia on Fatigue among Cancer Survivors: A Secondary Analysis of a Randomized Controlled Trial

    by Krista M Greeley, Joshua Rash, Joshua Tulk, Josée Savard, Melanie Seal, Robin Urquhart, John Thoms, Kara Laing, Emily Fawcett, Sheila N Garland

    STUDY OBJECTIVES: Cancer-related fatigue is one of the most common symptoms in cancer survivors. Cognitive behavioural therapy for insomnia (CBT-I) can improve fatigue, but mechanisms are unclear. This secondary analysis of a randomized controlled trial evaluated whether CBT-I led to a significant improvement in fatigue, accounting for change in comorbid symptoms of insomnia, perceived cognitive impairment (PCI), anxiety, and depression. The parent study evaluated the impacts of CBT-I on PCI and insomnia. METHODS: Cancer survivors with insomnia and PCI were randomized to CBT-I or a sleep-self monitoring waitlist control. Fatigue was measured using the Multidimensional Fatigue Symptom Inventory – Short Form at pre-, mid-, and post-treatment. Significant improvement in fatigue was defined as a reduction >10.79 points. Insomnia, PCI, anxiety and depression symptoms were assessed. A linear mixed model evaluated whether CBT-I improved fatigue after adjusting for comorbidities. Mediation analyses examined whether change in comorbidities accounted for the effect of CBT-I on fatigue. RESULTS: The sample consisted of 132 cancer survivors (77% female, Mage=60.12 years, 41% breast cancer). There was a significant group-by-time interaction on fatigue, p<.001, with the CBT-I group experiencing a 20.6-point reduction in fatigue compared to 3.7-points in the control. Improvements in fatigue were fully accounted for by improvements in the comorbidities with change in insomnia accounting for 45.3% of the effect observed in fatigue. CONCLUSIONS: CBT-I resulted in significant improvement in fatigue, and these effects were largely accounted for by change in insomnia. CBT-I is a robust intervention with efficacy for improving fatigue among cancer survivors.


  • Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors

    by Sheila N. Garland, Joshua Tulk, Josée Savard, Joshua A. Rash, Sondria Browne, Robin Urquhart, Melanie Seal, John Thoms, Kara Laing

    PURPOSE: Comorbid insomnia and cancer-related cognitive impairment (CRCI) are experienced by up to 26% of individuals diagnosed with cancer. This study examined the efficacy and durability of cognitive behavioral therapy for insomnia (CBT-I) on perceived CRCI in cancer survivors. METHODS: Atlantic Canadian cancer survivors with insomnia and CRCI were randomly assigned to receive seven weekly virtual CBT-I sessions (n = 63) or placed in a waitlist control group (n = 69) to receive treatment after the waiting period. Participants completed assessments at baseline, 1 month (mid-treatment), and 2 months (post-treatment). Age- and education-adjusted mixed-effects models using intention-to-treat principles assessed change at post-treatment. Data from both groups were then pooled to assess the durability of effects at 3 and 6 months. A mediation analysis examined whether change in insomnia symptoms mediated the effect of CBT-I on cognitive outcomes. RESULTS: The mean age of the sample was 60 years, 77% were women, and breast cancer was the most common diagnosis (41%). The treatment group reported an 11.35-point reduction in insomnia severity, compared with a 2.67-point reduction in the waitlist control group ( P < .001). The treatment group had a greater overall improvement than the waitlist control on perceived cognitive impairment ( P < .001; d = 0.75), cognitive abilities ( P < .001; d = 0.92), and impact on quality of life ( P < .001; d = 1.01). These improvements were maintained at follow-up. Change in insomnia symptoms fully mediated the effect of CBT-I on subjective cognitive outcomes. CONCLUSION: Treating insomnia with CBT-I produces clinically meaningful and durable improvements in CRCI. There is an urgent need increase access to evidence-based treatment for insomnia in cancer centers and the community.


  • Open Access

    An Evaluation of Racial and Ethnic Representation in Research Conducted with Young Adults Diagnosed with Cancer: Challenges and Considerations for Building More Equitable and Inclusive Research Practices

    by Sharon H. J. Hou, Anika Petrella, Joshua Tulk, Amanda Wurz, Catherine M. Sabiston, Jackie Bender, Norma D’agostino, Karine Chalifour, Geoff Eaton, Sheila N. Garland, et al.

    The psychosocial outcomes of adolescents and young adults (AYAs) diagnosed with cancer are poorer compared to their peers without cancer. However, AYAs with cancer from diverse racial and ethnic groups have been under-represented in research, which contributes to an incomplete understanding of the psychosocial outcomes of all AYAs with cancer. This paper evaluated the racial and ethnic representation in research on AYAs diagnosed with cancer using observational, cross-sectional data from the large Young Adults with Cancer in Their Prime (YACPRIME) study. The purpose was to better understand the psychosocial outcomes for those from diverse racial and ethnic groups. A total of 622 participants with a mean age of 34.15 years completed an online survey, including measures of post-traumatic growth, quality of life, psychological distress, and social support. Of this sample, 2% (n = 13) of the participants self-identified as Indigenous, 3% (n = 21) as Asian, 3% (n = 20) as “other,” 4% (n = 25) as multi-racial, and 87% (n = 543) as White. A one-way ANOVA indicated a statistically significant difference between racial and ethnic groups in relation to spiritual change, a subscale of post-traumatic growth, F(4,548) = 6.02, p < 0.001. Post hoc analyses showed that those under the “other” category endorsed greater levels of spiritual change than those who identified as multi-racial (p < 0.001, 95% CI = [2.49,7.09]) and those who identified as White (p < 0.001, 95% CI = [1.60,5.04]). Similarly, participants that identified as Indigenous endorsed greater levels of spiritual change than those that identified as White (p = 0.03, 95% CI = [1.16,4.08]) and those that identified as multi-racial (p = 0.005, 95% CI = [1.10,6.07]). We provided an extensive discussion on the challenges and limitations of interpreting these findings, given the unequal and small sample sizes across groups. We concluded by outlining key recommendations for researchers to move towards greater equity, inclusivity, and culturally responsiveness in future work.


  • Open Access

    Describing and Exploring Coping Strategies among Those Diagnosed with Cancer as an Adolescent or Young Adult: A YACPRIME Study

    by Amanda Wurz, Anika Petrella, Joshua Tulk, Catherine M. Sabiston, Fiona Schulte, Jackie Bender, Norma D’agostino, Sharon H. J. Hou, Geoff Eaton, Karine Chalifour, et al.

    A greater understanding of how young people cope with a cancer diagnosis is needed in order to inform age-appropriate supportive care. This paper describes the coping strategies used and explores relationships between coping strategies and personal, medical, and psychological variables among young adults (YAs) diagnosed with cancer. YAs (n = 547, mean age = 34.05 ± 6.00 years) completed an online survey, including the Brief COPE and measures of psychological functioning. Descriptive statistics and bivariate correlations were computed. Acceptance, self-distraction, positive reframing, and planning were the most used coping strategies by this sample. There were small (r = −0.09) to large (r = 0.51) significant relationships between personal, medical, and psychological variables and selected coping strategies. Coping with a cancer diagnosis early in life remains poorly understood. Identifying additional correlates and exploring inter- and intrapersonal variation in coping strategy use is required.


  • Understanding sleep quality in a national cohort of young adult cancer survivors: Results from the YACPRIME study

    by Sheila N. Garland, Joshua Tulk, Riley Cotter, Eric S. Zhou, Lauren C. Daniel, Fiona S.M. Schulte, Jacqueline L. Bender, Karine Chalifour, Geoff Eaton


  • Open Access

    An Investigation of Social Status among Adolescents and Young Adults Who Have Been Diagnosed with Cancer in Canada

    by Fiona S. M. Schulte, Sharon H. J. Hou, Jacqueline L. Bender, Joshua Tulk, Amanda Wurz, Anika Petrella, Catherine M. Sabiston, Norma D’agostino, Karine Chalifour, Geoff Eaton, et al.

    Background: Aims were to: (1) compare social status among AYAs diagnosed with cancer to a community population; (2) describe AYAs’ change in employment/education status; and (3) examine predictors of social status. Method: Social status (i.e., education, employment, relationship status, and living arrangement) was captured from young adults diagnosed with cancer recruited via social media through a community-based organization from across Canada and randomly matched to a community sample by sex, age, province of residence, total household income and race/ethnicity at a ratio of 1:3. Results: AYAs with cancer (N = 622) were an average of 4.45 (SD = 5.42) years from the completion of treatment and were less likely to be employed (χ2 = 96.35, p < 0.001) and more likely to be living at home with parents (χ2 = 17.00, p < 0.001). There were no differences in education or relationship status. Overall, 41% and 45% of AYAs reported quitting school or work, respectively. Non-metastatic disease (AOR 3.23, 95% CI 1.08–9.62), and better physical (AOR 1.07 95% CI 1.04–1.10) and mental quality of life (QOL)(AOR 1.06 95% CI 1.03–1.09), were associated with employment. Worse mental QOL (AOR 1.04 95% CI 1.01–1.07), less post-traumatic growth (AOR 1.01 95% CI 1.00–1.03), and social support (AOR 0.27, 95% CI 0.18–0.41) were associated with being single. Non-White race (AOR 3.19 95% CI 1.02–9.97) and less post-traumatic growth (AOR 0.97 95% CI 0.95–0.99) were associated with living with parents. Conclusions: AYAs diagnosed with cancer experience differences in attainment of employment and independent living compared to a community sample. These challenges may have implications for physical and mental QOL.


  • Rural‐urban differences in distress, quality of life, and social support among Canadian young adult cancer survivors: A Young Adults with Cancer in Their Prime (YACPRIME) study

    by Joshua Tulk, Amanda Wurz, Sharon H. J. Hou, Jacqueline Bender, Fiona S. M. Schulte, Geoff Eaton, Karine Chalifour, Sheila N. Garland

    Purpose: Geographic location plays a significant role in the health and wellbeing of those with cancer. This project explored the impact of rurality and social support on distress and quality of life in young adults (YAs) with cancer in Canada.Methods: The current research analyzed data from the Young Adults with Cancer in Their Prime (YACPRIME) study. Participants completed measures of emotional distress (10‐item Kessler Psychological Distress Scale), quality of life (12‐item Short‐form Health Survey), and social support (Medical Outcomes Study—Social Support Survey). Rural and urban‐dwelling survivors were compared using MANOVAs. Bivariate analyses were conducted to explore associations between distress and social support.Findings: Of the sample (N = 379), 26% identified their location as rural. Rural YA cancer survivors reported higher distress and worse physical health‐related quality of life (HRQOL) than survivors from urban areas but similar levels of mental‐health‐related quality of life. Social support appeared to have a marginally greater effect on psychosocial outcomes for urban participants. All types of social support were associated with lower levels of distress. However, different types of social support were associated more strongly with distress depending on a participant's geography.Conclusions: Rural‐dwelling YA cancer survivors experience significantly more distress and poorer physical HRQOL than urban‐dwelling survivors. Different needs and preferences for social support may influence the psychological health of rural cancer survivors. Additional research is needed to determine how best to understand and address distress in rural YAs with cancer.